Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26363882 | 0.82 | ALDH1A1 (0.36) | MEN1KMT2ARIPK1 | |
| SCHEMBL2937689 | 0.81 | ATM (0.34) | ATMNR1H2 | |
| SCHEMBL11998894 | 0.81 | CHRNB2 (0.43) | ATMNR1H2 | |
| SCHEMBL10223196 | 0.81 | NAMPT (0.35) | NAMPTATMMEN1KMT2ARIPK1 | |
| SCHEMBL26363888 | 0.80 | NAMPT (0.37) | NAMPTMEN1KMT2ARIPK1 | |
| SCHEMBL20026858 | 0.79 | ATM (0.41) | ATMNR1H2 | |
| SCHEMBL20111131 | 0.78 | NR1H2 (0.53) | NAMPTNR1H2MEN1KMT2A | |
| SCHEMBL21165813 | 0.78 | CHRNB2 (0.48) | NAMPTATMNR1H2 | |
| SCHEMBL22361409 | 0.76 | CHRNB2 (0.48) | NAMPTATMNR1H2 | |
| SCHEMBL21165842 | 0.76 | TACR1 (0.36) | NAMPTATMMEN1KMT2ARIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | NAMPT 2630/4885ATM 3611/4885NR1H2 601/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | NAMPT 2630/4885ATM 3611/4885NR1H2 601/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | NAMPT 1191/4885ATM 4725/4885NR1H2 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.